Premium
Outcomes of HPV‐related nasal squamous cell carcinoma
Author(s) -
Chowdhury Naweed,
Alvi Sameer,
Kimura Kyle,
Tawfik Ossama,
Manna Pradip,
Beahm David,
Robinson Ann,
Kerley Spencer,
Hoover Larry
Publication year - 2017
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.26477
Subject(s) - medicine , oncology , incidence (geometry) , malignancy , cohort , population , biopsy , physics , environmental health , optics
Background Human papilloma virus (HPV) infection has been shown to play an integral role in the development and prognosis of various head and neck cancers. Generational changes in sexual behavior may have led to an increased incidence of positivity in recent years. HPV positivity in both benign and malignant lesions of the sinonasal cavities has been shown in previous studies (estimates range from 20%–30% for malignancy). We intend to investigate if HPV positivity affected survival outcomes in our patient cohort. Methods/Materials Twenty‐six patients diagnosed pathologically for sinonasal squamous cell carcinoma (SCC) with available archived biopsy specimens were retrospectively analyzed to obtain HPV status using a real‐time, multiplex polymerase chain reaction assay that detects and quantifies 15 known high‐risk HPV types. Demographic information was collected, and survival analyses were performed using the Kaplan‐Meier estimation. Results Sixteen of 26 (62%) SCC tumors in the patient cohort were positive for HPV DNA. HPV types 16 and 18 were the most common (n = 8 and 2, respectively), although a wide range of HPV types across the 15 tested were positive. Survival analyses showed a statistically significant survival advantage (median survival of 12 vs. 54 months) when accounting for HPV positivity using log‐rank testing ( P < 0.003). Conclusion HPV positivity appears to be present in a significant proportion of squamous cell carcinoma cases of the nasal cavity. In our limited patient population there does appear to be a survival advantage to HPV positivity. Further prospective, multi‐institutional trials with standardized treatment protocols are needed to elucidate the true impact of HPV positivity in this subset of head and neck cancers. Level of Evidence 4. Laryngoscope , 127:1600–1603, 2017